Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Both CVS Health and The Cigna Group trade on Wall Street’s health-care complex, but their recent price performance diverged sharply, underscoring how investors weigh growth, margin outlook, and competitive risk in managed care.
THE APEX TIMES
THE APEX TIMES
Pfizer says the U.S. FDA has approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for adults who have unresectable locally advanced or metastatic HER2-positive disease, positioning the therapy as a maintenance option intended to avoid ongoing chemotherapy.
THE APEX TIMES
A regulatory stock-sale filing from Eli Lilly’s biggest shareholder is drawing attention at the same time Wall Street analysts are increasing their outlook for the drugmaker, creating a two-announcement read for investors.
THE APEX TIMES
Eli Lilly reported 48% revenue growth in the second quarter of 2026 and lifted its full-year outlook, but the stock was trading at 30.94 times forward earnings as of Oct. 6, below its longer-run average multiple, according to a market report.
THE APEX TIMES
A recent Yahoo Finance item said Zacks.com users have been searching Pfizer (PFE) shares frequently, directing attention to the factors that typically shape a large pharma company’s stock outlook.
THE APEX TIMES
A Yahoo Finance recap focused on why Eli Lilly and Company is gaining watchlist momentum among Zacks.com users, pointing readers to consider what could drive the next phase of the stock.
THE APEX TIMES
In a new Q-and-A with Jean Reidy, CVS Health points older adults to practical steps for staying on track as temperatures drop and the year winds down.
THE APEX TIMES
A fresh Medicare Advantage quality score update moved investor sentiment sharply in managed-care stocks, lifting Humana by about 16%, pulling CVS Health down, and leaving UnitedHealth roughly unchanged.
THE APEX TIMES
A bearish note points to a sharp projected drop in CVS Health’s mix of Medicare Advantage members in plans rated 4.5 stars or higher, raising concerns about reimbursement and profitability.
